<DOC>
	<DOCNO>NCT01669239</DOCNO>
	<brief_summary>This prospective , multicenter , single-arm , phase II study evaluate safety neoadjuvant liposomal doxorubicin plus paclitaxel , trastuzumab , pertuzumab patient HER2-positive breast cancer</brief_summary>
	<brief_title>Study Neoadjuvant Myocet® , Paclitaxel , Pertuzumab , Trastuzumab HER2-positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Written inform consent study procedure accord local regulatory requirement prior begin specific protocol procedure Female patient Age 1874 year ECOG Performance Status 0 1 Histologically confirm , untreated , invasive breast carcinoma stage IIIIIB Tumor size &gt; 2 cm clinical radiological assessment HER2+ invasive BC accord ASCO/CAP guideline Known hormone receptor status possibility assessment Adequate organ function define : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 10**9/L Hemoglobin ( Hgb ) ≥ 9 g/dL Platelets &gt; 100 x 10**9/L Creatinine ≤ 1.6 mg/dL ALT AST ≤ 2.5 x ULN Alkaline phosphatase ≤ 5 ULN Total bilirubin ≤ 1.5 mg/dL Baseline LVEF ≥ 55 % measure echocardiogram MUGA scan Negative βHCG pregnancy test ( serum ) premenopausal woman reproductive capacity ( biologically capable child ) woman less 12 month menopause . All subject biologically capable child must agree commit use reliable method birth control 2 week administration first dose investigational product 28 day last dose investigational product Absence psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Clinical radiologic evidence metastatic disease time study entry Prior chemotherapy , radiotherapy , surgery BC , excision tumor contralateral breast , provide patient previously receive adjuvant radiotherapy chemotherapy Subjects concurrently active second malignancy , adequately treat non melanoma skin cancer , situ melanoma situ cervical cancer . Subjects nonmammary malignancy must diseasefree least 5 year Known suspected hypersensitivity reaction investigational therapeutic compound incorporate substance Presence CHF LVEF &lt; 55 % Clinically significant ( i.e . active ) cardiovascular disease , include cerebrovascular accident ( &lt; 6 month enrollment ) , unstable angina pectoris , myocardial infarction ≤ 6 month enrollment , uncontrolled hypertension ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) , highrisk uncontrolled arrhythmias Uncontrolled diabetes mellitus , active peptic ulcer disease , uncontrolled epilepsy Active uncontrolled infection time enrolment History significant comorbidities , judgment investigator , may interfere conduction study , evaluation response , informed consent Use investigational agent participation another therapeutic clinical trial concurrently previous 30 day enrollment Patients pregnant breastfeed Women childbearing potential unable unwilling use acceptable contraceptive measure Inability unwillingness abide study protocol cooperate fully investigator designee</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Liposomal doxorubicin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Pertuzumab</keyword>
	<keyword>Safety</keyword>
</DOC>